Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bempikibart - Q32 Bio

Next Previous
Search
Drug Profile

Bempikibart - Q32 Bio

Alternative Names: ADX-914; BMS-986265

Latest Information Update: 18 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Q32 Bio
  • Class Anti-inflammatories; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action CRLF2 protein antagonists; Interleukin 7 receptor alpha subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alopecia areata; Atopic dermatitis; Autoimmune disorders
  • No development reported Inflammation

Most Recent Events

  • 10 Mar 2025 Efficacy, adverse event and pharmacokinetic data from a phase II trial in Alopecia areata released by Q32 Bio
  • 10 Dec 2024 Adverse events and efficacy data from a SIGNAL-AA phase IIa proof-of-concept trial in alopecia areata was released by Q32 Bio
  • 10 Dec 2024 Adverse events and efficacy data from a SIGNAL-AD phase IIa proof-of-concept trial in atopic dermatitis was released by Q32 Bio

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top